Champion Homes Inc
Consumer products
Champion Homes Inc (SKY) Stock News
The latest SKY headlines and market coverage — 10 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Exploring SKYRIZI's Exceptional Growth: Revenue and Market Expansion Analysis
SKYRIZI, AbbVie's IL-23 inhibitor, has achieved blockbuster status with global sales reaching $11.7 billion in 2024 (51% YoY growth). The drug is expanding across multiple indications including psoriasis, psoriatic arthritis, and IBD, with strong gastroenterology uptake and favorable dosing schedules. AbbVie forecasts combined revenues for SKYRIZI and Rinvoq to exceed $31 billion annually by 2027, positioning SKYRIZI as the largest contributor to its $26.7 billion immunology portfolio.
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Arcosa, Inc. (NYSE – ACA), Fathom Holdings Inc. (Nasdaq – FTHM), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Arcosa (CRH acquisition for $150/share), Fathom Holdings (Bed Bath & Beyond acquisition), Nuvalent (GSK acquisition for $124/share), and Dana Incorporated (Eaton Corporation acquisition).
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB)
Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties to shareholders. The investigations concern AstroNova (being acquired by Arcline for $29.00/share), Open Lending (being acquired by ANV Group for $3.15/share), Huntsman (merging with Olin in a stock exchange), and Standard BioTools (being acquired by Treeline Biosciences). The firm is seeking shareholders to discuss whether fair processes were conducted and fair value provided.
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)
Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).
- GlobeNewswire Inc.·
UPDATED: Forward Industries Announces Letter of Intent to Acquire SkyAI, Inc. (SKYA)
Forward Industries (NASDAQ: FWDI) announced a non-binding all-stock acquisition proposal to SkyAI (SKYA), offering 0.367 FWDI shares per SKYA share, representing a 20% premium to SKYA's closing price of $1.29. SKYA did not respond to the proposal by the June 12, 2026 deadline. Forward argues the combination would benefit SKYA shareholders by providing exposure to Forward's Solana treasury platform and stronger institutional positioning.
- Benzinga·
EDWARD SMOLYANSKY, KEY LWAY SHAREHOLDER: TERMINATION OF POISON PILL MARKS IMPORTANT INFLECTION POINT FOR LIFEWAY SHAREHOLDERS AS GOVERNANCE QUESTIONS MOUNT AHEAD OF THE ELECTION
Edward Smolyansky, largest shareholder and former COO of Lifeway Foods, criticizes the Board's governance, stating the poison pill was only terminated after ISS recommended voting against all directors. He highlights a pattern of reactive governance, the reversal of a board refresh process, and calls for shareholders to vote against incumbent directors at the June 17 Annual Meeting to register dissatisfaction with the Board's conduct.
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Dominion Energy, Inc. (NYSE – D), Global Business Travel Group, Inc. (NYSE – GBTG), Webster Financial Corporation (NYSE – WBS), TopBuild Corp. (NYSE – BLD)
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Dominion Energy (NextEra acquisition), Global Business Travel Group (Long Lake Management acquisition), Webster Financial (Banco Santander acquisition), and TopBuild Corp (QXO acquisition).
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)
Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA)
Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from approximately $1.9 billion to $2.4 billion.